RNA virus error catastrophe: Direct molecular test by using ribavirin

RNA viruses evolve rapidly. One source of this ability to rapidly change is the apparently high mutation frequency in RNA virus populations. A high mutation frequency is a central tenet of the quasispecies theory. A corollary of the quasispecies theory postulates that, given their high mutation frequency, animal RNA viruses may be susceptible to error catastrophe, where they undergo a sharp drop in viability after a modest increase in mutation frequency. We recently showed that the important broad-spectrum antiviral drug ribavirin (currently used to treat hepatitis C virus infections, among others) is an RNA virus mutagen, and we proposed that ribavirin's antiviral effect is by forcing RNA viruses into error catastrophe. However, a direct demonstration of error catastrophe has not been made for ribavirin or any RNA virus mutagen. Here we describe a direct demonstration of error catastrophe by using ribavirin as the mutagen and poliovirus as a model RNA virus. We demonstrate that ribavirin's antiviral activity is exerted directly through lethal mutagenesis of the viral genetic material. A 99.3% loss in viral genome infectivity is observed after a single round of virus infection in ribavirin concentrations sufficient to cause a 9.7-fold increase in mutagenesis. Compiling data on both the mutation levels and the specific infectivities of poliovirus genomes produced in the presence of ribavirin, we have constructed a graph of error catastrophe showing that normal poliovirus indeed exists at the edge of viability. These data suggest that RNA virus mutagens may represent a promising new class of antiviral drugs.

[1]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[2]  E. Domingo,et al.  Virus mutation frequencies can be greatly underestimated by monoclonal antibody neutralization of virions , 1989, Journal of virology.

[3]  J. Arnold,et al.  Poliovirus RNA-dependent RNA Polymerase (3Dpol) , 2000, The Journal of Biological Chemistry.

[4]  V. Knight,et al.  Biochemistry and clinical applications of ribavirin , 1986, Antimicrobial Agents and Chemotherapy.

[5]  P. Palese,et al.  Antigenic variants of influenza viruses: marked differences in the frequencies of variants selected with different monoclonal antibodies. , 1980, Virology.

[6]  C. Pringle Genetic Characteristics of Conditional Lethal Mutants of Vesicular Stomatitis Virus Induced by 5-Fluorouracil, 5-Azacytidine, and Ethyl Methane Sulfonate , 1970, Journal of virology.

[7]  J. B. Antczak,et al.  Studies on the mechanism of the antiviral activity of ribavirin against reovirus. , 1989, Virology.

[8]  C. Schmaljohn,et al.  Antibody-selected variation and reversion in Sindbis virus neutralization epitopes , 1986, Journal of virology.

[9]  E. Domingo,et al.  Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus , 1997, Journal of virology.

[10]  A. Cann,et al.  Location and primary structure of a major antigenic site for poliovirus neutralization , 1983, Nature.

[11]  J. Arnold,et al.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen , 2000, Nature Medicine.

[12]  E. Domingo,et al.  Viruses at the edge of adaptation. , 2000, Virology.

[13]  E. Pfefferkorn,et al.  Isolation and characterization of conditional-lethal mutants of Sindbis virus. , 1966, Virology.

[14]  B. Sherry,et al.  Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14 , 1986, Journal of virology.

[15]  P. Wyde Respiratory syncytial virus (RSV) disease and prospects for its control. , 1998, Antiviral research.

[16]  V. Knight,et al.  Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. , 1985, Antiviral research.

[17]  E. Domingo,et al.  RNA virus mutations and fitness for survival. , 1997, Annual review of microbiology.

[18]  J. Mullins,et al.  Lethal mutagenesis of HIV with mutagenic nucleoside analogs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Drake,et al.  Mutation rates among RNA viruses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Holland,et al.  RNA virus populations as quasispecies. , 1992, Current topics in microbiology and immunology.

[21]  R. Andino,et al.  Poliovirus Requires a Precise 5′ End for Efficient Positive-Strand RNA Synthesis , 2000, Journal of Virology.

[22]  J. McCormick,et al.  Lassa fever. Effective therapy with ribavirin. , 1986, The New England journal of medicine.

[23]  G. Belsham,et al.  Studies on the infectivity of foot-and-mouth disease virus RNA using microinjection. , 1988, The Journal of general virology.

[24]  Stephen S. Morse,et al.  The Evolutionary biology of viruses , 1994 .

[25]  Charles Weissmann,et al.  Nucleotide sequence heterogeneity of an RNA phage population , 1978, Cell.

[26]  R. J. Bauer,et al.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Crainic,et al.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site , 1986, Journal of virology.

[28]  J. Holland,et al.  High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Katherine Spindler,et al.  Rapid evolution of RNA genomes. , 1982, Science.

[30]  J. Parvin,et al.  Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1 , 1986, Journal of virology.

[31]  R. K. Robins,et al.  THE RELATIONSHIP BETWEEN THE METABOLISM OF RIBAVIRIN AND ITS PROPOSED MECHANISM OF ACTION , 1977, Annals of the New York Academy of Sciences.

[32]  V. Knight,et al.  Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. , 1985, Antiviral research.

[33]  R. K. Robins,et al.  Antiviral mechanisms of action. , 1980, Annual review of pharmacology and toxicology.

[34]  J. Holland,et al.  High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus , 1989, Journal of virology.

[35]  W. Kirkpatrick,et al.  Ribavirin, a broad spectrum antiviral agent , 1980 .

[36]  R. K. Robins,et al.  Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.

[37]  P. Harvey The evolutionary biology of viruses: edited by Stephen S. Morse Raven Press, 1994. $87.00 hbk (xi + 353 pages) ISBN 0781701198 , 1994 .

[38]  Christopher J. Miller,et al.  Mucosal Immunization of Cynomolgus Macaques with Two Serotypes of Live Poliovirus Vectors Expressing Simian Immunodeficiency Virus Antigens: Stimulation of Humoral, Mucosal, and Cellular Immunity , 1999, Journal of Virology.

[39]  M. Eigen,et al.  The origin of genetic information: viruses as models. , 1993, Gene.

[40]  H. Eggers,et al.  Coxsackie A9 Virus: Mutation from Drug Dependence to Drug Independence , 1965, Science.

[41]  David A. Steinhauer,et al.  Mutation Frequencies at Defined Single Codon Sites in Vesicular Stomatitis Virus and Poliovirus Can Be Increased Only Slightly by Chemical Mutagenesis , 1990, Journal of virology.

[42]  E. Domingo,et al.  Very high frequency of reversion to guanidine resistance in clonal pools of guanidine-dependent type 1 poliovirus , 1990, Journal of virology.

[43]  P. Sharp,et al.  An inducible mammalian amber suppressor: Propagation of a poliovirus mutant , 1987, Cell.

[44]  J. Miller,et al.  A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[46]  Pedro R. Lowenstein,et al.  Response of Foot-and-Mouth Disease Virus to Increased Mutagenesis: Influence of Viral Load and Fitness in Loss of Infectivity , 2000, Journal of Virology.